One of them is a Phase I trial, testing the safety and preliminary therapeutic efficacy of CCT303-406 cells in 15 patients with HER-2-positive stage IV solid tumors (that have failed standard treatment of relapsed or difficult-to-treat), including BC. Here, ERBB2 is linked to breast cancer.